

Company Overview

Intellipharma International Inc. is a pharmaceutical company specializing in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Intellipharma has developed several drug delivery systems based on this technology platforms, with a pipeline of products (some of which have received FDA approval) in various stages of development. The Company has ANDA and NDA 505 (b)(2) drug delivery product candidates in its development pipeline in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain.

NASDAQ Schedules Hearing to Consider Intellipharma's (TM) Continued Listing

Dec 4 2018, 9:52 PM EST

Intellipharma Announces FDA Final Approval of Generic Effexor® XR

Nov 27 2018, 5:05 PM EST

Intellipharma Submits Investigational New Drug Application to the U.S. FDA for IPCI006 (oxycodone hydrochloride immediate release) Tablets Incorporating its Abuse Deterrent and Overdose Resistant Technology

Nov 27 2018, 8:00 AM EST

Stock Overview

Symbol	IPCI
Exchange	Nasdaq
Market Cap	2.57m
Last Price	\$0.2673
52-Week Range	\$0.266 - \$10.50

Investor Relations

Intellipharma International Inc.
 30 Worcester Road
 Toronto, ON M9W 5X2
 T: 416-798-3001
investors@intellipharma.com

12/07/2018 04:00 PM EST

Management Team

Isa Odidi, Ph.D., MBA

Chairman, CEO, Co-Chief Scientific Officer (CSO)

Amina Odidi, Ph.D.

President, COO, Co-Chief Scientific Officer (CSO)

Patrick N. Yat, Ph.D.

Vice President, Chemistry & Analytical Services

Christian Akyempon, B.Sc. (Honors), M.Sc., MBA

Vice President, Commercial Operations

Intellipharma International Inc.

30 Worcester Road
 Toronto, ON M9W 5X2
 Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 20-F and its quarterly reports. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.